C.A. Ngoh

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

E De Cock, Persefoni Kritikou, Mariana Sandoval et al. · PLoS ONE · 2016 · 100 citations · Full text

Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea

Eui‐Kyung Lee, Cédric Révil, C.A. Ngoh et al. · Clinical Therapeutics · 2012 · 18 citations

Surgical Oncology, Gastrointestinal Oncology, South Korea +8

Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute

Simon Rule, Javier Briones, Rodney B.W. Smith et al. · Value in Health · 2014 · 15 citations · Full text

Lymphoid Neoplasia, Oncology, Immunology +7

Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer

Tamlyn Rautenberg, Uwe Siebert, Dirk Arnold et al. · Journal of Medical Economics · 2013 · 10 citations · Full text